- $394.95m
- -$58.86m
- $97.67m
Somalogic Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Somalogic Enters Into 2nd Amendment To Master Collaboration Agreement With Novartis Pharma AG
Brief: Somalogic Announces Preliminary Full Year 2022 Revenue And Provides Organizational And Strategic Updates
Brief: Somalogic Reports Q3 Financial Results
Somalogic Inc reports results for the quarter ended in September - Earnings Summary
Somalogic Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Somalogic Appointments Troy Cox As Executive Chairman Of Board Of Directors
Brief: Somalogic Reports Q2 2022 Financial Results
Brief: Somalogic Acquires DNA Nanotechnology Leader Palamedrix To Develop The Next-Generation Somascan® Assay
Brief: Somalogic Announces License Agreement With Oncohost For The Development Of Precision Cancer Diagnostics
Brief: SomaLogic Reports Fourth Quarter Loss Per Share Of $0.13
SomaLogic gains on upbeat 2022 revenue forecast
Brief: Somalogic Sees FY Revenue About $105 Million To $110 Million
Brief: Somalogic Announces Preliminary Revenue For Full Year 2021 Above Guidance Range
SomaLogic jumps on partnership with Illumina
Brief: Somalogic Inc - Grants Illumina Rights To Use Certain Of Co’S Intellectual Property To Develop Licensed Products Under Agreement
Brief: SomaLogic Announces Exclusive Partnership With Illumina To Develop Sequencing-Based Proteomic Solutions
Brief: Somalogic Reports Third Quarter 2021 Financial Results
Brief: Somalogic Announces Strategic Collaboration With University Hospitals Cleveland Medical Center To Treat Diabetic Patients At High Risk Of Cardiovascular Disease